Raf Kinase Inhibitory Protein Down-Expression Exacerbates Hepatic Fibrosis In Vivo and In Vitro

Quanfang Huang1, Chunhong Liang, Ling Wei

  • 1The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, China.

Abstract

Insights

Decreased Raf kinase inhibitory protein (RKIP) expression worsens chronic liver injury and liver fibrosis by promoting hepatic stellate cell proliferation and collagen production. Lower RKIP levels correlate with increased liver damage.

Area of Science:

  • Hepatology
  • Molecular Biology
  • Oncology

Background:

  • Raf kinase inhibitory protein (RKIP) is implicated in tumor development.
  • The role of RKIP in chronic liver injury and fibrosis remains unclear.

Purpose of the Study:

  • To investigate the role of RKIP in liver fibrosis.
  • To determine the effect of RKIP expression levels on liver injury and fibrosis progression.

Main Methods:

  • Hepatic fibrosis induced in rats using porcine serum (PS).
  • Primary rat hepatic stellate cells (HSCs) isolated.
  • RKIP expression modulated using locostatin.

Main Results:

  • Down-regulating RKIP exacerbated liver injury, collagen deposition, and elevated ALT, AST, and TNF-α.
  • Reduced RKIP promoted HSC proliferation, collagen production, α-SMA, MMP-1, and MMP-2 expression.
  • Decreased RKIP activated ERK and TLR4 signaling pathways.

Conclusions:

  • RKIP expression is inversely correlated with the severity of liver injury and fibrosis.
  • Reduced RKIP expression exacerbates chronic liver injury and liver fibrosis.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
307
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.6K